Blue Jet Healthcare Ltd - Stock Valuation and Financial Performance

BSE: 544009 | NSE: BLUEJET | Pharmaceuticals & Drugs | Small Cap

Blue Jet Healthcare Share Price

520.60 -17.45 -3.24%
as on 13-Nov'24 13:29

DeciZen - make an informed investing decision on Blue Jet Healthcare

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Blue Jet Healthcare stock performance -

mw4me loader
P/E Ratio (SA):
55.59
Market Cap:
9,333.3 Cr.
52-wk low:
319.4
52-wk high:
567.9

Is Blue Jet Healthcare Ltd an attractive stock to invest in?

1. Is Blue Jet Healthcare Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Blue Jet Healthcare Ltd is a average quality company.

2. Is Blue Jet Healthcare Ltd undervalued or overvalued?

The key valuation ratios of Blue Jet Healthcare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Blue Jet Healthcare Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Blue Jet Healthcare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Blue Jet Healthcare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Blue Jet Healthcare Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 50%54%36.2%28.9%-
Value Creation
Index
2.73.01.61.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 499683721712722
Sales YoY Gr.-37%5.5%-1.3%-
Adj EPS 7.99.88.38.99.7
YoY Gr.-23.9%-14.8%6.7%-
BVPS (₹) 19.630.139.348.753.3
Adj Net
Profit
137170145154168
Cash Flow from Ops. 135146142241-
Debt/CF from Ops. 0.4000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA12.6%-1.3%
Adj EPS NANA4.1%6.7%
BVPSNANA35.5%24%
Share Price - - - 30.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
40.339.424.120.219
Op. Profit
Mgn %
41.536.530.432.430.7
Net Profit
Mgn %
27.524.920.121.723.3
Debt to
Equity
0.20000
Working Cap
Days
0214260290172
Cash Conv.
Cycle
0110137140121

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 12.56%

Return on Equity has declined versus last 3 years average to 19.00%

Net Profit has been subdued in last 3 years 4.05%

Sales growth is not so good in last 4 quarters at -2.77%

Latest Financials - Blue Jet Healthcare Ltd.

Standalone Consolidated
TTM EPS (₹) 9.7 8
TTM Sales (₹ Cr.) 722 499
BVPS (₹.) 53.3 0
Reserves (₹ Cr.) 889 330
P/BV 10.10 0.00
PE 55.59 67.43
From the Market
52 Week Low / High (₹) 319.40 / 567.90
All Time Low / High (₹) 319.40 / 567.90
Market Cap (₹ Cr.) 9,333
Equity (₹ Cr.) 34.7
Face Value (₹) 2
Industry PE 44.1

Management X-Ray of Blue Jet Healthcare:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Blue Jet Healthcare

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24
Sales499683721712
Operating Expenses 292434502482
Manufacturing Costs53656858
Material Costs169287336314
Employee Cost 29334253
Other Costs 41495657
Operating Profit 207249219229
Operating Profit Margin (%) 41.5%36.5%30.4%32.2%
Other Income 9192429
Interest 5310
Depreciation 20222528
Exceptional Items 000-10
Profit Before Tax 190243217220
Tax 49625756
Profit After Tax 142182160164
PAT Margin (%) 28.4%26.6%22.2%23.0%
Adjusted EPS (₹)8.210.59.29.4
Dividend Payout Ratio (%)0%0%0%11%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 340522681845
Share Capital 10353535
Reserves 330487647811
Minority Interest0000
Debt36000
Long Term Debt29000
Short Term Debt7000
Trade Payables60575430
Others Liabilities 158220271339
Total Liabilities 5937981,0071,214

Fixed Assets

Gross Block176215231276
Accumulated Depreciation375880104
Net Fixed Assets139156151172
CWIP 3330147
Investments 3794189250
Inventories118105126130
Trade Receivables144227239177
Cash Equivalents 70886685
Others Assets83124205254
Total Assets 5937981,0071,214

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 135146142241
PBT 190243217220
Adjustment 1771819
Changes in Working Capital -73-76-3313
Tax Paid 0-28-60-11
Cash Flow From Investing Activity -56-76-147-264
Capex -49-21-59-174
Net Investments -8-55-88-91
Others 1000
Cash Flow From Financing Activity -27-56-4-2
Net Proceeds from Shares 0000
Net Proceeds from Borrowing -8-2900
Interest Paid -5-4-10
Dividend Paid 0000
Others -14-23-3-2
Net Cash Flow 5114-10-24
PARTICULARSMar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)41.6742.1626.621.45
ROCE (%)50.0354.0136.2428.85
Asset Turnover Ratio0.840.980.80.64
PAT to CFO Conversion(x)0.950.80.891.47
Working Capital Days
Receivable Days10599118107
Inventory Days86595866
Payable Days128746049

Blue Jet Healthcare Ltd Stock News

Blue Jet Healthcare Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Blue Jet Healthcare on 13-Nov-2024 13:29 is ₹520.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Nov-2024 13:29 the market cap of Blue Jet Healthcare stood at ₹9,333.3.
The latest P/E ratio of Blue Jet Healthcare as of 13-Nov-2024 13:29 is 55.59.
The latest P/B ratio of Blue Jet Healthcare as of 13-Nov-2024 13:29 is 10.10.
The 52-week high of Blue Jet Healthcare is ₹567.9 and the 52-week low is ₹319.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Blue Jet Healthcare is ₹721.9 ( Cr.) .

About Blue Jet Healthcare Ltd

The company was originally incorporated as ‘Jet Chemicals Private Limited,’ under the provisions of the Companies Act, 1956, at Mumbai, pursuant to a certificate of incorporation dated December 7, 1968, issued by the Registrar of Companies, Maharashtra at Mumbai. Pursuant to the company’s Shareholders’ resolution dated December 28, 2020, the name of the company was changed to ‘Blue Jet Healthcare Private Limited’, and a fresh certificate of incorporation dated December 30, 2020, was issued by the Registrar of Companies, Maharashtra at Mumbai. Subsequently, the company was converted into a public limited company, and pursuant to a special resolution of its Shareholders dated May 5, 2022, and the name of the company was changed to ‘Blue Jet Healthcare Limited’ A fresh certificate of incorporation was issued by Registrar of Companies, Maharashtra, at Mumbai on May 18, 2022. 

The company is a speciality pharmaceutical and healthcare ingredients and intermediates company, offering niche products targeted toward innovator pharmaceutical companies and multi-national generic pharmaceutical companies. Since its incorporation in 1968, it has established a contract development and manufacturing organization (CDMO) business model with specialized chemistry capabilities in contrast media intermediates and high intensity sweeteners, on the back of strategic and early investments in research and development (R&D) and manufacturing infrastructure. It has competencies and manufacturing capabilities in contrast media intermediates and high-intensity sweeteners, including saccharin and its salts. The company manufactures a range of products in-house, including the key starting intermediate and advanced intermediates, which allows it to control its production process for consistent quality and cost effectiveness.

The company has built a long-term customer base with innovator pharmaceutical companies and multi-national generic pharmaceutical companies, supported by committed multi-year contracts of up to five years. The company’s ‘Collaboration, Development, Manufacturing’ approach has been, and will continue to be, critical to its success and a key factor for growing its CDMO business. Its product capabilities across the pharmaceutical and healthcare categories have evolved with its customers’ needs, supported by its manufacturing capabilities and technology-driven product development. Its operations are primarily organized in three product categories: (i) contrast media intermediates, (ii) high intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients (APIs).

Business area of the company

The company is a global, science-led, pharmaceutical company evolved as Strategic Partner for Collaboration, Development & Manufacturing of advance Pharmaceutical Intermediates and API. 

Key awards, accreditations or recognitions

  • 2014: The company was awarded a certification of registration by the United Registrar of Systems in recognition of its quality management system which complies with ISO 9001: 2015 and in recognition of its environmental management system which complies with ISO 14001:2015 standards.
  • 2021: The company was awarded a certification by BQSR Quality Assurance Private to certify that its Occupational Health and Safety Management System conformed with the requirements of ISO 45001:2018. 

Major events and milestones

  • 1968: Established as Jet Chemicals Private Limited in Shahad (Unit I) by the late Shri B L Arora.
  • 1970: Began manufacturing saccharin and its salts, which are high-intensity sweeteners.
  • 2000: Entered the x-ray contrast media sector, with a basic building block (5- NIPA).
  • 2002: Commenced the manufacturing of pharma intermediates and API.
  • 2003: Established Blue Circle Organics Private Limited (at Unit-II, Ambernath facility).
  • 2017: Commenced semi-automated manufacturing block for contrast media intermediate business.
  • 2019: Received USFDA Establishment Inspection Report of Blue Circle Organics Private Limited for Unit II.
  • 2019: As part of the company’s corporate restructure strategy, a merger between Blue Circle Organics Private Limited and Jet Chemicals Private Limited was undertaken to form Blue Jet Healthcare Private Limited.
  • 2020: Acquisition of brownfield site in Mahad on a leasehold basis (i.e., Unit III).
  • 2021: Acquisition of greenfield site in Ambernath on a leasehold basis (i.e., Unit IV).


Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.